Followers | 653 |
Posts | 83299 |
Boards Moderated | 0 |
Alias Born | 05/25/2008 |
Monday, April 27, 2015 6:38:19 PM
Immune Pharmaceuticals is currently conducting a search for an appropriate partner for the final development and commercialization of AmiKet, which is ready for Phase III clinical trial in post herpetic neuralgia and has been granted Orphan Drug Designation by the Food and Drug Administration. The Company expects to select a partner and secure a licensing agreement by the second quarter of 2015. The topical nanoparticle formulation of AmiKet will be developed collaboratively by Immune and Yissum upon the execution of a license agreement between the parties and will be part of the AmiKet commercialization agreement.
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM